Rapid Evidence Reviews COVID-19

The COVID-19 Evidence Review Group for Medicines was established to support the HSE in managing the significant amount of information on treatments for COVID-19.  This COVID-19 Evidence Review Group is comprised of evidence synthesis practitioners from across the National Centre for Pharmacoeconomics (NCPE), Medicines Management Programme (MMP) and the National Medicines Information Centre (NMIC).


Prophylactic Therapy


Hydroxychloroquine and Azithromycin Combination Therapy


Intravenous Immunoglobulin